Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Magnus T Dillon, Jeane Guevara,Kabir Mohammed,Emmanuel Christian Patin,Simon A Smith,Emma Dean,Gemma N Jones,Sophie E Willis, Marcella Petrone, Carlos Silva,Khin Thway,Catey Bunce,Ioannis Roxanis,Pablo Nenclares,Anna Wilkins,Martin McLaughlin, Adoracion Jayme-Laiche,Sarah Benafif, Georgios Nintos,Vineet Kwatra,Lorna Grove,David C Mansfield,Paula Proszek,Philip Martin, Luiza Moore,Karen E Swales,Udai Banerji,Mark P Saunders,James Spicer,Martin D Forster,Kevin J Harrington The Journal of clinical investigation（2023）
摘要
AstraZeneca provided funding for components of the clinical conduct of PATRIOT and drug supply and labelling.
更多查看译文
关键词
atr inhibition,ceralasertib,genomic defects,tumors
AI 理解论文
溯源树
样例
